Univariate analysis of risk factors for chronic GVHD development
. | No. of evaluable cases . | No. of events . | Probability, % (95% confidence interval) . | P . |
|---|---|---|---|---|
| Patient age | ||||
| Younger than 50 y | 32 | 18 | 56 (39-73) | NS |
| 50 y or older | 36 | 25 | 61 (45-77) | |
| Donor age | ||||
| Younger than 50 y | 40 | 24 | 60 (45-75) | NS |
| 50 y or older | 28 | 19 | 69 (52-86) | |
| Sex | ||||
| Female donor | 33 | 22 | 67 (51-83) | NS |
| Male donor | 35 | 21 | 60 (44-76) | |
| CMV serologic status | ||||
| Seronegative pair | 11 | 10 | 91 (64-100) | NS |
| Other | 57 | 33 | 58 (45-71) | |
| ABO | ||||
| Major mismatch | 24 | 13 | 54 (34-74) | NS |
| Other | 44 | 30 | 68 (54-82) | |
| Diagnosis | ||||
| Hematologic malignancy | 51 | 32 | 63 (50-76) | NS |
| Other malignant disease | 17 | 11 | 65 (42-88) | |
| Disease status | ||||
| Standard risk | 14 | 7 | 50 (24-76) | NS |
| Advanced disease | 54 | 36 | 67 (54-79) | |
| Stem cell source | ||||
| Bone marrow | 33 | 16 | 49 (32-66) | .01 |
| PBSC | 35 | 27 | 77 (63-91) | |
| ATG dose infused during conditioning | ||||
| High | 31 | 15 | 48 (42-72) | .02 |
| Low | 37 | 28 | 76 (56-90) | |
| Acute GVHD | ||||
| Grade 0 | 24 | 11 | 46 (26-66) | .03 |
| Grades I-IV | 44 | 32 | 72 (59-85) |
. | No. of evaluable cases . | No. of events . | Probability, % (95% confidence interval) . | P . |
|---|---|---|---|---|
| Patient age | ||||
| Younger than 50 y | 32 | 18 | 56 (39-73) | NS |
| 50 y or older | 36 | 25 | 61 (45-77) | |
| Donor age | ||||
| Younger than 50 y | 40 | 24 | 60 (45-75) | NS |
| 50 y or older | 28 | 19 | 69 (52-86) | |
| Sex | ||||
| Female donor | 33 | 22 | 67 (51-83) | NS |
| Male donor | 35 | 21 | 60 (44-76) | |
| CMV serologic status | ||||
| Seronegative pair | 11 | 10 | 91 (64-100) | NS |
| Other | 57 | 33 | 58 (45-71) | |
| ABO | ||||
| Major mismatch | 24 | 13 | 54 (34-74) | NS |
| Other | 44 | 30 | 68 (54-82) | |
| Diagnosis | ||||
| Hematologic malignancy | 51 | 32 | 63 (50-76) | NS |
| Other malignant disease | 17 | 11 | 65 (42-88) | |
| Disease status | ||||
| Standard risk | 14 | 7 | 50 (24-76) | NS |
| Advanced disease | 54 | 36 | 67 (54-79) | |
| Stem cell source | ||||
| Bone marrow | 33 | 16 | 49 (32-66) | .01 |
| PBSC | 35 | 27 | 77 (63-91) | |
| ATG dose infused during conditioning | ||||
| High | 31 | 15 | 48 (42-72) | .02 |
| Low | 37 | 28 | 76 (56-90) | |
| Acute GVHD | ||||
| Grade 0 | 24 | 11 | 46 (26-66) | .03 |
| Grades I-IV | 44 | 32 | 72 (59-85) |
NS indicates not significant.